International Journal of Colorectal Disease

, Volume 20, Issue 2, pp 137–146

Molecular detection of clinical colorectal cancer metastasis: how should multiple markers be put to use?

  • Michael Conzelmann
  • Ulrich Linnemann
  • Martin R. Berger
Original Article


Background and aims

Up to 45% of colorectal cancer (CRC) patients will develop local recurrence or metastasis following curative resection. The latter is due to cells shed from the primary carcinoma prior to or during surgery. The aim of this study was to contribute toward a “rational”-approach for detecting these disseminated tumor cells (DTC) using a combination of independent markers and detection methods.


Liver, lymph node, and bone marrow samples from 246 CRC patients were screened for DTC using three markers: mutated K-ras was detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), and cytokeratin 20 (CK20) and guanylylcyclase C (GCC), indicating circulating epithelial cells, were tracked by nested reverse-transcription (RT) PCR.


The rate of positive findings of the individual markers (CK20: 88%; GCC: 88%; K-ras: 67%) and their combinations (88–50%) was significantly higher in biopsies from liver metastases than in liver samples from patients without evident distant metastasis (M0; p<0.03). The detection rate of individual markers (except GCC) was also significantly elevated in inconspicuous liver tissue adjacent to metastasis compared with specimens from M0 patients. When using the concomitant detection of all three markers as criterion for DTC in the liver of M0 patients, however, no patient was DTC-positive. Therefore, the concomitant presence of the two CEC markers (CK20 plus GCC) and/or the presence of mutated K-ras were preferred for a combined evaluation, which resulted in a 24% detection rate for biopsies from both liver lobes. This translates into 39% of M0 patients with at least one positive liver biopsy.


Our results suggest that the concomitant detection of CK20 plus GCC and/or the presence of mutated K-ras are a rational approach for tracking CEC/DTC in CRC patients.


Cytokeratin 20 Guanylylcyclase C K-ras Disseminated tumor cells Circulating epithelial cells 


  1. 1.
    Bosman FT (1995) Prognostic value of pathological characteristics of colorectal cancer. Eur J Cancer 31A:1216–1221CrossRefPubMedGoogle Scholar
  2. 2.
    Goldberg RM, Fleming TR, Tangen CM, Moertel CG, Macdonald JS, Haller DG, Laurie JA (1998) Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med 129:27–35PubMedGoogle Scholar
  3. 3.
    Kune GA, Kune S, Field B, White R, Brough W, Schellenberger R, Watson LF (1990) Survival in patients with large-bowel cancer. Dis Colon Rectum 33:938–946PubMedGoogle Scholar
  4. 4.
    Cagir B, Gelmann A, Park J, Fava T, Tenkelevitch A, Bittner EW, Weaver EJ, Palazzo JP, Weinberg D, Fry RD, Waldmann SA (1999) Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann Intern Med 131:805–812PubMedGoogle Scholar
  5. 5.
    Conzelmann M, Dieterle CP, Linnemann U, Berger MR (2003) Cytokeratin 20 and guanylylcyclase C mRNA is largely present in lymph node and liver specimens of colorectal cancer patients. Int J Cancer 107:617–628CrossRefPubMedGoogle Scholar
  6. 6.
    Dieterle CP, Conzelmann M, Linnemann U, Berger MR (2004) Investigation of isolated tumor cells by PCR-RFLP detection of K-ras mutations in tumor, mucosa, liver, lymph node and bone marrow samples of 199 colorectal cancer patients. Clin Cancer Res 10:641–650PubMedGoogle Scholar
  7. 7.
    Futamura M, Takagi Y, Koumura H, Kida H, Tanemura H, Shimokawa K, Saji S (1998) Spread of colorectal cancer micrometastases in regional lymph nodes by reverse transcriptase-polymerase chain reactions for carcinoembryonic antigen and cytokeratin 20. J Surg Oncol 68:34–40CrossRefPubMedGoogle Scholar
  8. 8.
    Lassmann S, Bauer M, Rosenberg R, Nekarda H, Soong R, Rüger R, Höfler H, Werner M (2004) Identification of occult tumor cells in node negative lymph nodes of colorectal cancer patients by cytokeratin 20 gene and protein expression. Int J Colorectal Dis 19:87–94CrossRefPubMedGoogle Scholar
  9. 9.
    Miyake Y, Yamamoto H, Fujiwara Y, Ohue M, Sugita Y, Tomita N, Sekimoto M, Matsuura N, Shiozaki H, Monden M (2001) Extensive micrometastases to lymph nodes as a marker for rapid recurrence of colorectal cancer: a study of lymphatic mapping. Clin Cancer Res 7:1350–1357PubMedGoogle Scholar
  10. 10.
    Nakamori S, Kameyama M, Furukawa H, Takeda O, Sugai S, Imaoka S, Nakamura Y (1997) Genetic detection of colorectal cancer cells in circulation and lymph nodes. Dis Colon Rectum 40 [Suppl]:29–36Google Scholar
  11. 11.
    Noura S, Yamamoto H, Ohnishi T, Masuda N, Matsumoto T, Takayama O, Fujunaga H, Miyake Y, Ikenaga M, Ikeda M, Sekimoto M, Mtsuura M, Monden M (2002) Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. J Clin Oncol 20:4232–4241CrossRefPubMedGoogle Scholar
  12. 12.
    Rosenberg R, Hoos A, Mueller J, Baier P, Stricker D, Werner M, Nekarda H, Siewert JR (2002) Prognostic significance of cytokeratin 20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients. J Clin Oncol 204:1049–1055CrossRefGoogle Scholar
  13. 13.
    SaltoTellez M, Kong SL, Leong APK, Koay ESC (2003) Intrinsic variability in the detection of micrometastases in lymph nodes for re-staging of colorectal cancer: effect of individual markers and tissue samples. Eur J Cancer 39:1234–1241CrossRefPubMedGoogle Scholar
  14. 14.
    Yun K, Merrie AEH, Gunn J, Phillips LV, McCall J (2000) Keratin 20 is a specific marker of submicroscopic lymph node metastases in colorectal cancer: validation by K-ras mutations. J Pathol 191:21–26CrossRefPubMedGoogle Scholar
  15. 15.
    Bustin SA, Siddiqi S, Ahmed S, Hands R, Dorudi S (2004) Quantification of cytokeratin 20, carcinoembryonic antigen and guanylyl cyclase C mRNA levels in lymph nodes may not predict treatment failure in colorectal cancer patients. Int J Cancer 108:412–417CrossRefPubMedGoogle Scholar
  16. 16.
    Bustin SA, Gyselman VG, Williams NS, Dorudi S (1999) Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients. Br J Cancer 7911/7912:1813–1820CrossRefGoogle Scholar
  17. 17.
    Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S (2000) Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg 232:58–65CrossRefPubMedGoogle Scholar
  18. 18.
    Guller U, Zajac P, Schnider A, Boesch B, Vorburger S, Zuber M, Spagnoli GC, Oertli D, Maurer R, Metzger U, Harder F, Heberer M, Marti WR (2002) Disseminated single tumor cells detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 236:768–776CrossRefPubMedGoogle Scholar
  19. 19.
    Wharton RQ, Jonas SK, Glover C, Khan ZAJ, Klokouzas A, Quinn H, Henry M, Allen-Mersh TG (1999) Increased detection of circulating tumor cells in the blood of colorectal carcinoma patients using two reverse transcription-PCR assays and multiple blood samples. Clin Cancer Res 5:4158–4163PubMedGoogle Scholar
  20. 20.
    Vlems FA, Diepstra JHS, Cornelissen IMHA, Ligtenberg MJL, Wobbes T, Punt CJA, van Krieken JHJM, Ruers TJM, van Muijen GNP (2003) Investigations for a multi-marker RT-PCR to improve sensitivity of disseminated tumor cell detection. Anticancer Res 23:179–186PubMedGoogle Scholar
  21. 21.
    Fujita S, Kudo N, Takayuki A, Moriya Y (2001) Detection of cytokeratin 19 and 20 mRNA in peripheral blood from colorectal cancer patients and their prognosis. Int J Colorectal Dis 16:141–146CrossRefPubMedGoogle Scholar
  22. 22.
    Hardingham JE, Hewett PJ, Sage RE, Finch JL, Nutall JD, Kotasek D, Dobrovic A (2000) Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int J Cancer 89:8–13CrossRefPubMedGoogle Scholar
  23. 23.
    Bosch B, Guller U, Schnider A, Maurer R, Harder F, Metzger U, Marti WR (2003) Perioperative detection of disseminated tumor cells is an independent prognostic factor in patients with colorectal cancer. Br J Surg 90:882–888CrossRefPubMedGoogle Scholar
  24. 24.
    Kienle P, Koch M, Autschbach F, Benner A, Treiber M, Wannenmacher M, von Knebel Doeberitz M, Büchler MW, Herfarth C, Weitz J (2003) Decreased detection rate of disseminated tumor cells of rectal cancer patients after preoperative chemoradiation. Ann Surg 238:324–331CrossRefPubMedGoogle Scholar
  25. 25.
    Aoki S, Takagi Y, Hayakawa M, Yamaguchi K, Futamura M, Kuneida K, Saji S (2002) Detection of peritoneal micrometastases by reverse transcriptase-polymerase chain reaction targeting carcinoembryonic antigen and cytokeratin 20 in colon cancer patients. J Exp Clin Cancer Res 21:555–562PubMedGoogle Scholar
  26. 26.
    Linnemann U, Schimanski CC, Gebhardt C, Berger MR (2004) Prognostic value of disseminated colorectal tumor cells in the liver: results of follow-up examinations. Int J Colorectal Dis 19:380–386CrossRefPubMedGoogle Scholar
  27. 27.
    Schimanski CC, Linnemann U, Berger MR (1999) Sensitive detection of k-ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Res 59:5169–5175PubMedGoogle Scholar
  28. 28.
    Yokoyama N, Shirai Y, Ajioka Y, Nagakura S, Suda T, Hatakeyama K (2002) Immunohistochemically detected hepatic micrometastases predict a high risk of intrahepatic recurrence after resection of colorectal carcinoma liver metastases. Cancer 94:1642–1647CrossRefPubMedGoogle Scholar
  29. 29.
    Klump B, Nehls O, Okech T, Hsieh CJ, Gaco V, Gittinger FS, Sarbia M, Borchard F, Greschniok A, Gruenagel HH, Porschen R, Gregor M (2004) Molecular lesions in colorectal cancer: impact on prognosis? Int J Colorectal Dis 19:23–42CrossRefPubMedGoogle Scholar
  30. 30.
    Carrithers SL, Barber MT, Biswas S, Parkinson SJ, Park PK, Goldstein SD, Waldmann SA (1996) Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissue. Proc Natl Acad Sci USA 93:14827–14832CrossRefPubMedGoogle Scholar
  31. 31.
    Vlems FA, Ruers TJM, Punt CJA, Wobbes T, van Muijen GNP (2003) Relevance of disseminated tumor cells in blood and bone marrow of patients with solid epithelial tumors in perspective. Eur J Surg Oncol 29:289–302CrossRefPubMedGoogle Scholar
  32. 32.
    Nordgard O, Aloysius TA, Todnem K, Heikkila R, Ogreid D (2003) Detection of lymph node micrometastases in colorectal cancer. Scand J Gastroenterol 2:125–132Google Scholar
  33. 33.
    Jung R, Krueger W, Hosch S, Holweg M, Kroeger N, Gutensohn K, Wagener C, Neumaier M, Zander AR (1998) Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro. Br J Cancer 789:1194–1198Google Scholar
  34. 34.
    Moll R, Löwe A, Laufer J, Franke WW (1992) Cytokeratin 20 in human carcinomas. Am J Pathol 140:427–447PubMedGoogle Scholar
  35. 35.
    Tot T (2002) Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur J Cancer 38:758–763CrossRefPubMedGoogle Scholar
  36. 36.
    Tot T (1999) Adenocarcinomas metastatic to the liver. Cancer 85:171–177CrossRefPubMedGoogle Scholar
  37. 37.
    Baisse B, Bouzourene H, Saraga EP, Bosman FT, Benhattar J (2001) Intratumoral genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer 93:346–352CrossRefPubMedGoogle Scholar
  38. 38.
    Schimanski CC, Linnemann U, Galle PR, Arbogast R, Berger MR (2003) Hepatic disseminated tumor cells in colorectal cancer UICC stage IV patients: prognostic implications. Int J Oncol 23:791–796PubMedGoogle Scholar
  39. 39.
    Safi F, Beyer HG (1993) The value of follow-up after curative surgery of colorectal carcinoma. Cancer Detect Prev 17:417–424PubMedGoogle Scholar
  40. 40.
    August DA, Ottow RT, Sugarbaker PH (1984) Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 3:303–324PubMedGoogle Scholar
  41. 41.
    Yamamoto N, Kato Y, Yanagisawa A, Ohta H, Takahashi T, Kitagawa T (1997) Predictive value of genetic diagnosis for cancer micrometastasis. Cancer 80:1393–1398CrossRefPubMedGoogle Scholar
  42. 42.
    Clarke GA, Ryan E, Crowe JP, O’Keane JC, MacMathuna P (2001) Tumor derived mutated K-ras codon 12 expression in regional lymph nodes of stage II colorectal cancer patients is not associated with increased risk of cancer related death. Int J Colorectal Dis 16:108–111CrossRefPubMedGoogle Scholar
  43. 43.
    Edler L, Ittrich C (2003) Biostatistical methods for the validation of alternative methods for in vitro toxicity testing. Altern Lab Anim 31:5–41Google Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Michael Conzelmann
    • 1
  • Ulrich Linnemann
    • 2
  • Martin R. Berger
    • 1
  1. 1.Unit of Toxicology and ChemotherapyGerman Cancer Research CenterHeidelbergGermany
  2. 2.Department of Visceral, Thoracic and Endocrine SurgeryMunicipal Hospital Nürnberg NordNürnbergGermany

Personalised recommendations